Trial Profile
A Phase 1, Open-Label Study to Assess the Relative Bioavailability, Effect of Food, and Gastric pH Modification on the Pharmacokinetics of TAK-931 in Patients With Advanced Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 25 Nov 2022
Price :
$35
*
At a glance
- Drugs Simurosertib (Primary) ; Esomeprazole
- Indications Solid tumours
- Focus Pharmacokinetics
- Sponsors Takeda Oncology
- 12 Nov 2022 Results published in the Investigational New Drugs
- 01 Jun 2022 Results from (NCT032619475 and NCT037082116) assessing the effect of TAK-931 on corrected QT (QTc) intervals at clinically relevant doses published in the Clinical Pharmacology in Drug Development
- 25 Sep 2021 Results of a Pop PK analysis characterizing sources of variability on PK of TAK-931 in adult patients with advanced solid tumors ; using data from three clinical studies: NCT02699749, NCT03261947 and NCT03708211 published in the Journal of Clinical Pharmacology